Page last updated: 2024-11-06

azauracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Azauracil is a synthetic pyrimidine analog that acts as an inhibitor of orotate phosphoribosyltransferase, an enzyme involved in the de novo synthesis of pyrimidine nucleotides. Azauracil has been investigated as a potential anticancer agent and has demonstrated antitumor activity in preclinical studies. Its mechanism of action involves inhibiting DNA and RNA synthesis, thereby disrupting cell growth and proliferation. Studies have explored its use in treating various cancers, including leukemia, lymphoma, and solid tumors. However, clinical trials have shown limited success due to its significant side effects. Further research is ongoing to optimize its therapeutic potential and minimize toxicity.'

azauracil: minor descriptor (64-72); major descriptor (73-86); on line search URACIL (66-74); URACIL/AA (75-86); INDEX MEDICUS search URACIL (64-72); AZAURACIL (73-86) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

6-azauracil : A 1,2,4-triazine compound having oxo-substituents at the 3- and 5-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID68037
CHEMBL ID2260276
CHEBI ID53745
SCHEMBL ID88056
SCHEMBL ID11714527
MeSH IDM0263166

Synonyms (71)

Synonym
17121-89-0
AKOS002364462
EN300-43776
3,5-dioxo-[1,2,4]triazine
nsc-3425
azauracil
461-89-2
nsc3425
nsc 3425
4(6)-azauracil
wln: t6nmvmvj
6-azauracil
as-triazine-3,5-diol
1,4-triazine-3,5(2h,4h)-dione
as-triazine-3,4h)-dione
usaf cb-30
1,2,4-triazine-3,5(2h,4h)-dione
2h-1,2,4-triazine-3,5-dione
6-azauracil, >=98%
ccris 2710
ai3-26412
1,2,4-triazine-3,5-diol
einecs 207-318-0
ipo 3834
as-triazine-3,5(2h,4h)-dione
A-9700
STK503788
A0558
1,2,4-triazine-3,5-dione
AKOS005136325
FT-0653168
s-triazine-3,5(2h,4h)-dione
CHEBI:53745 ,
STK644293
AKOS002303248
[1,2,4]triazine-3,5-diol
unii-i14twn70lr
i14twn70lr ,
18802-37-4
A827001
A813205
6-aza-2,4-dihydroxypyrimidine
3,5-dihydroxy-1,2,4-triazine
2,3,4,5-tetrahydro-1,2,4-triazine-3,5-dione
BP-20136
FT-0601065
CHEMBL2260276
SCHEMBL88056
AKOS022061544
AM83920
3,5-dioxo-(2h,4h)-1,2,4-triazine
2h-[1,2,4]triazine-3,5-dione
2h-[1,2,4]triazin-3,5-dione
3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-hydroxy-1,2,4-triazin-5(4h)-one
DTXSID2060042
mfcd00006456
SY031517
SCHEMBL11714527
DS-1403
BS-3739
6-aza-uracil
AC-22511
1,2,4-triazine-3,5(2h,4h)-dione,dihydro-
Z276509088
CS-W008232
Q27124185
STL185513
SB73703
A851355
HY-W008232

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"High throughput screening (HTS) of our compound file provided an attractive lead compound with modest P2X(7) receptor antagonist potency and high selectivity against a panel of receptors and channels, but also with high human plasma protein binding and a predicted short half-life in humans."( Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.
Beaulieu, AM; Chang, SP; Dombroski, MA; Duplantier, AJ; Gabel, CA; Jordan, C; Kalgutkar, AS; Kraus, KG; Labasi, JM; Mussari, C; Perregaux, DG; Shepard, R; Subramanyam, C; Taylor, TJ; Trevena, KA; Whitney-Pickett, C; Yoon, K, 2011
)
0.6

Dosage Studied

ExcerptRelevanceReference
" We found that the 6AU sensitivity of the rpo21 mutants can be suppressed by increasing the dosage of the wild-type PPR2 gene, presumably as a result of overexpression of TFIIS."( Genetic interaction between transcription elongation factor TFIIS and RNA polymerase II.
Archambault, J; Friesen, JD; Lacroute, F; Ruet, A, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
1,2,4-triazinesAny compound with a 1,2,4-triazine skeleton, in which nitrogen atoms replace carbon at positions 1, 2 and 4 of the core benzene ring structure.
nucleobase analogueA molecule that can substitute for a normal nucleobase in nucleic acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (161)

TimeframeStudies, This Drug (%)All Drugs %
pre-199089 (55.28)18.7374
1990's18 (11.18)18.2507
2000's32 (19.88)29.6817
2010's20 (12.42)24.3611
2020's2 (1.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.97 (24.57)
Research Supply Index5.12 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index34.82 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.60%)5.53%
Reviews1 (0.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other164 (98.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]